Notal Vision, Inc. products

A home-based monitoring program supporting earlier detection of wet AMD in intermediate dry AMD patients. FDA-Cleared and Covered by Medicare and Most Private Insurance. The progression from dry Age-related Macular Degeneration (AMD) to wet AMD can occur rapidly and lead to severe vision loss if left undiagnosed and untreated. ForeseeHome® allows physicians to detect wet AMD earlier, and help preserve functional vision in patients at risk by beginning treatment earlier.

Notal Vision is committed to transforming the detection and diagnosis of ocular diseases. As new therapies come to market and the population ages, the costs of delivering healthcare continue to rise. Extending ophthalmic and systemic disease management beyond the clinic can positively impact the economics of healthcare as well as the medical benefits for patients.

Notal Vision is developing a first-of-its-kind Artificial Intelligence-enabled digital diagnostic for patients with neovascular retina diseases using our patient-operated Home Optical Coherence Tomography device. The first disease in the Notal Home OCT Program pipeline is neovascular Age-related Macular Degeneration (AMD)

The Notal OCT Analyzer (NOA^TM) is a computational image analysis algorithm designed to provide automated detection of fluid in exudative retinal diseases including wet Age-Related Macular Degeneration, macular edema, and retinal vein occlusions. NOA uses a machine learning algorithm and image recognition computational technique to distinguish between normal morphologic structures and those associated with disease-related changes that occur as a result of fluid that is present under and within the retina. With performance validated in a clinical trial that compared NOA’s sensitivity, specificity, and accuracy with that of three retinal specialists¹, the algorithm has multiple commercial applications including the analyses of data generated in patients’ homes with Notal Vision’s home-OCT device.